XVIPF (Xvivo Perfusion AB) Institutional Ownership: 30.60% (As of Jun. 26, 2026)


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $42.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Institutional Ownership?

Xvivo Perfusion AB XVIPF -1.32% 91 Institutional Ownership is 30.60% as of Jun. 26, 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xvivo Perfusion AB's institutional ownership is 30.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xvivo Perfusion AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xvivo Perfusion AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Xvivo Perfusion AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Institutional Ownership Chart

Xvivo Perfusion AB Historical Data

The historical data trend for Xvivo Perfusion AB can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31
Institutional Ownership 33.57 30.69 25.99 25.35 25.70 28.85 28.41 29.36 27.97 27.74
XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 30.60% mean?
Xvivo Perfusion AB (XVIPF) has a Institutional Ownership of 30.60% as of Jun. 26, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Institutional Ownership too high?
Xvivo Perfusion AB's current Institutional Ownership is 30.60%. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Institutional Ownership compare to ABT and SYK?
Xvivo Perfusion AB's Institutional Ownership of 30.60% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Devices & Instruments company?
A good Institutional Ownership depends on the Medical Devices & Instruments industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Institutional Ownership is 30.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Institutional Ownership is 30.60%. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Institutional Ownership is 30.60% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • Institutional Ownership: 30.60%
  • GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$42.07
GF Value